Company Profile
Biohaven Stock Price, News & Analysis
- Ticker:
- BHVN
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
14.42 USD (+5.80%)
Close
Last updated: August 6, 2026
1.53B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, BHVN closed up 5.80% at $14.42. No new same-company headline was identified in the current news window.
Company overview
Business overview
Biohaven is a biopharmaceutical company focused on neuroscience, immunology, and rare disease. Its business combines commercial assets with a pipeline aimed at multiple specialty indications.
Geographic Base and Sector Classification
Biohaven is headquartered in the United States and listed on NASDAQ. It sits in specialty biopharma with a strong neuroscience footprint.
Business Model Characteristics
The company depends on product sales, launch execution, and pipeline expansion across CNS and immune-mediated disease. Investors watch revenue, development milestones, and strategic execution.
Position Within the Biotechnology Landscape
Biohaven occupies a premium specialty-biopharma niche within biotech. It has both commercial grounding and catalyst sensitivity, which keeps the stock lively.
Future catalysts
Biohaven’s catalysts are its neuroscience pipeline, especially migraine and related CNS programs, plus any update that broadens the commercial story. The company remains one of the cleaner CNS growth names if execution holds.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Biohaven (BHVN)?
Biohaven (BHVN) most recently closed at 14.42 USD, a +5.80% move versus the previous session.
What is the market cap of Biohaven (BHVN)?
Biohaven currently has a market capitalization of 1.53B USD on BioPharmSignal.
What does Biohaven do?
Biohaven is a biopharmaceutical company focused on neuroscience, immunology, and rare disease. Its business combines commercial assets with a pipeline aimed at multiple specialty indications.
On which exchange is BHVN stock listed?
Biohaven (BHVN) is associated with NYSE, United States, Biopharma.
What is Biohaven?
Biohaven’s catalysts are its neuroscience pipeline, especially migraine and related CNS programs, plus any update that broadens the commercial story.
Which conditions is Biohaven targeting with Biohaven?
Biohaven is associated with immunology, rare disease, neuroscience based on its company overview and current catalyst commentary.
How does Biohaven describe recent progress with Biohaven?
Biohaven’s catalysts are its neuroscience pipeline, especially migraine and related CNS programs, plus any update that broadens the commercial story.
What future catalysts are investors watching for Biohaven?
Biohaven’s catalysts are its neuroscience pipeline, especially migraine and related CNS programs, plus any update that broadens the commercial story. The company remains one of the cleaner CNS growth names if execution holds.